Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tewari

Showing results (71-80 of 349) with videos related to

Pageof 35
Sort By:
Therapeutics and Clinical Risk Management|November 23, 2018
Targeted treatment of advanced ovarian cancer: spotlight on rucaparibDiana C Pearre, Krishnansu S Tewari
Clinical Pharmacology : Advances and Applications|June 1, 2013
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinomaTaylor J Brueseke, Krishnansu S Tewari
European Journal of Gynaecological Oncology|October 31, 2000
On the evolution of a successful treatment program for a solid tumor systemK S Tewari, P J Disaia
Drugs in Context|January 11, 2019
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinationsMarisa C Liu, Krishnansu S Tewari
Future Oncology (London, England)|November 21, 2019
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancerCarolyn E Haunschild, Krishnansu S Tewari
Expert Opinion on Drug Discovery|February 22, 2018
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancerJuliet E Wolford, Krishnansu S Tewari
Onkologie|October 10, 2009
Beyond platinum for metastatic and recurrent carcinoma of the cervixKrishnansu S Tewari, Bradley J Monk
Future Oncology (London, England)|June 4, 2015
US FDA oncology drug approvals in 2014Juliet E Wolford, Krishnansu S Tewari
Clinical Pharmacology : Advances and Applications|October 15, 2013
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancerRamez N Eskander, Krishnansu S Tewari
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2014
New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapyKrishnansu S Tewari, Bradley J Monk
Pageof 35

Showing results (71-80 of 349) with videos related to

Sort By:
Pageof 35
Therapeutics and Clinical Risk Management|November 23, 2018
Targeted treatment of advanced ovarian cancer: spotlight on rucaparibDiana C Pearre, Krishnansu S Tewari
Clinical Pharmacology : Advances and Applications|June 1, 2013
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinomaTaylor J Brueseke, Krishnansu S Tewari
European Journal of Gynaecological Oncology|October 31, 2000
On the evolution of a successful treatment program for a solid tumor systemK S Tewari, P J Disaia
Drugs in Context|January 11, 2019
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinationsMarisa C Liu, Krishnansu S Tewari
Future Oncology (London, England)|November 21, 2019
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancerCarolyn E Haunschild, Krishnansu S Tewari
Expert Opinion on Drug Discovery|February 22, 2018
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancerJuliet E Wolford, Krishnansu S Tewari
Onkologie|October 10, 2009
Beyond platinum for metastatic and recurrent carcinoma of the cervixKrishnansu S Tewari, Bradley J Monk
Future Oncology (London, England)|June 4, 2015
US FDA oncology drug approvals in 2014Juliet E Wolford, Krishnansu S Tewari
Clinical Pharmacology : Advances and Applications|October 15, 2013
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancerRamez N Eskander, Krishnansu S Tewari
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2014
New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapyKrishnansu S Tewari, Bradley J Monk
Pageof 35